<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349892</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiac SABR</org_study_id>
    <nct_id>NCT03349892</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia</brief_title>
  <official_title>Stereotactic Ablative Radiotherapy (SABR) for Refractory Ventricular Tachycardia - a Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the&#xD;
      maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac&#xD;
      myocardium and to make a preliminary assessment of the efficacy of the treatment. The dose&#xD;
      escalation will be guided by Time-to-Event Continual Reassessment Method (TITE-CRM) to ensure&#xD;
      more patients will be spared dose limiting toxicities and more patients will be entered on&#xD;
      the dose level that will be chosen as minimal dose of maximal effect. This design also allows&#xD;
      for continual accrual of patients when delayed adverse events may be observed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICD (Implantable Cardioverter Defibrillator) Shock Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>ICD (implantable cardioverter defibrillator) shock free survival at six months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Salvage Definitive Anti-arrhythmia Therapy (Cardiac Transplant)</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of salvage definitive anti-arrhythmia therapy (cardiac transplant) over 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Return of Ventricular Tachycardia Requiring Defibrillation, Intravenous Drug Therapy or Readmission to Hospital</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of return of ventricular tachycardia requiring defibrillation, intravenous drug therapy or readmission to hospital over 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ICD Shocks</measure>
    <time_frame>12 months post-SABR procedure</time_frame>
    <description>Incidence of ICD shocks 12 months post-SABR procedure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Decline of LV Ejection Fraction by More Than 5% on Two Consecutive Echocardiograms</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of decline of LV ejection fraction by more than 5% on two consecutive echocardiograms over 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Persistent Increase in Baseline Supplemental Oxygen Requirement by 1L for a Duration of &gt;3 Months</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of persistent increase in baseline supplemental oxygen requirement by 1L for a duration of &gt;3 months over 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Steroid Use for Radiotherapy Related Indications</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Followed for 10 years +</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Refractory Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Stereotactic Ablation Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single-arm, non-blinded study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiotherapy (SABR)</intervention_name>
    <description>A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
    <arm_group_label>Stereotactic Ablation Treatment Arm</arm_group_label>
    <other_name>external beam radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Documented sustained ventricular arrhythmias refractory to or not a suitable candidate for&#xD;
        catheter based RFA ablative therapy&#xD;
&#xD;
          -  Documented sustained ventricular arrhythmias refractory to or not a suitable candidate&#xD;
             for cardiac sympathetic denervation therapy&#xD;
&#xD;
          -  Documented ventricular arrhythmias refractory to or not a suitable candidate for&#xD;
             cardiac transplantation&#xD;
&#xD;
          -  Documented sustained ventricular arrhythmias refractory to or not a suitable candidate&#xD;
             for additional medical management&#xD;
&#xD;
          -  ICD in place with documented episodes recurrent VT despite best clinical management&#xD;
             previous refusal of ICD with recurrent sustained ventricular arrhythmias&#xD;
&#xD;
          -  If ischemic cardiomyopathy, myocardial infarction occurred more than one month prior&#xD;
             to enrollment&#xD;
&#xD;
          -  No history of prior radiotherapy to the chest&#xD;
&#xD;
          -  Prescribed dose must be deliverable using SABR technique&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) &gt; 70&#xD;
&#xD;
          -  If a woman is of childbearing potential, a negative serum pregnancy test must be&#xD;
             documented. Women of childbearing potential must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; or abstinence) for at least 4 weeks&#xD;
             after study treatment.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Department of Radiation Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6951</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <results_first_submitted>July 21, 2021</results_first_submitted>
  <results_first_submitted_qc>October 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2021</results_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Robert K. Chin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03349892/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stereotactic Ablation Treatment Arm</title>
          <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Documented sustained ventricular arrhythmias refractory to or not suitable for cardiac transplantation, cardiac sympathetic denervation therapy, catheter based RFA ablative therapy or other medical management.</population>
      <group_list>
        <group group_id="B1">
          <title>Stereotactic Ablation Treatment Arm</title>
          <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ICD (Implantable Cardioverter Defibrillator) Shock Free Survival</title>
        <description>ICD (implantable cardioverter defibrillator) shock free survival at six months</description>
        <time_frame>6 months</time_frame>
        <population>Patients with refractory VT.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>ICD (Implantable Cardioverter Defibrillator) Shock Free Survival</title>
          <description>ICD (implantable cardioverter defibrillator) shock free survival at six months</description>
          <population>Patients with refractory VT.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Salvage Definitive Anti-arrhythmia Therapy (Cardiac Transplant)</title>
        <description>Incidence of salvage definitive anti-arrhythmia therapy (cardiac transplant) over 5 years.</description>
        <time_frame>5 years</time_frame>
        <population>Single participant was lost to followup prior to 5-year assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Salvage Definitive Anti-arrhythmia Therapy (Cardiac Transplant)</title>
          <description>Incidence of salvage definitive anti-arrhythmia therapy (cardiac transplant) over 5 years.</description>
          <population>Single participant was lost to followup prior to 5-year assessment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Return of Ventricular Tachycardia Requiring Defibrillation, Intravenous Drug Therapy or Readmission to Hospital</title>
        <description>Incidence of return of ventricular tachycardia requiring defibrillation, intravenous drug therapy or readmission to hospital over 5 years</description>
        <time_frame>5 years</time_frame>
        <population>Study participant was lost to follow-up prior to 5-year assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Return of Ventricular Tachycardia Requiring Defibrillation, Intravenous Drug Therapy or Readmission to Hospital</title>
          <description>Incidence of return of ventricular tachycardia requiring defibrillation, intravenous drug therapy or readmission to hospital over 5 years</description>
          <population>Study participant was lost to follow-up prior to 5-year assessment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of ICD Shocks</title>
        <description>Incidence of ICD shocks 12 months post-SABR procedure</description>
        <time_frame>12 months post-SABR procedure</time_frame>
        <population>Subject was followed for 28 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of ICD Shocks</title>
          <description>Incidence of ICD shocks 12 months post-SABR procedure</description>
          <population>Subject was followed for 28 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Decline of LV Ejection Fraction by More Than 5% on Two Consecutive Echocardiograms</title>
        <description>Incidence of decline of LV ejection fraction by more than 5% on two consecutive echocardiograms over 5 years</description>
        <time_frame>5 years</time_frame>
        <population>Subject was not followed for 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Decline of LV Ejection Fraction by More Than 5% on Two Consecutive Echocardiograms</title>
          <description>Incidence of decline of LV ejection fraction by more than 5% on two consecutive echocardiograms over 5 years</description>
          <population>Subject was not followed for 5 years</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Persistent Increase in Baseline Supplemental Oxygen Requirement by 1L for a Duration of &gt;3 Months</title>
        <description>Incidence of persistent increase in baseline supplemental oxygen requirement by 1L for a duration of &gt;3 months over 5 years</description>
        <time_frame>5 years</time_frame>
        <population>Subject was not followed for 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Persistent Increase in Baseline Supplemental Oxygen Requirement by 1L for a Duration of &gt;3 Months</title>
          <description>Incidence of persistent increase in baseline supplemental oxygen requirement by 1L for a duration of &gt;3 months over 5 years</description>
          <population>Subject was not followed for 5 years</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Steroid Use for Radiotherapy Related Indications</title>
        <time_frame>5 years</time_frame>
        <population>Subject was not followed for 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Steroid Use for Radiotherapy Related Indications</title>
          <population>Subject was not followed for 5 years</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Survival</title>
        <time_frame>Followed for 10 years +</time_frame>
        <population>Subject was not followed for 10 years</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Ablation Treatment Arm</title>
            <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Subject was not followed for 10 years</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stereotactic Ablation Treatment Arm</title>
          <description>This is a single-arm, non-blinded study.&#xD;
Stereotactic Ablative Radiotherapy (SABR): A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert K. Chin, MD, PhD , Assistant Clinical Professor</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>(310) 825-9771</phone>
      <email>rkchin@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

